A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants With Major Depressive Disorder (MDD)
Janssen Research & Development, LLC
Summary
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Eligibility
- Age range
- 18–64 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI) * Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode * Were first diagnosed with depression before the age of 55 * Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months * Hav…
Interventions
- DrugJNJ-89495120
JNJ-89495120 will be administered.
- DrugPlacebo
Placebo will be administered.
Locations (44)
- UAB Huntsville Regional Medical CampusHuntsville, Alabama
- Chandler Clinical TrialsChandler, Arizona
- IMA Clinical Research PC PhoenixPhoenix, Arizona
- Noble Clinical ResearchTucson, Arizona
- University of ArizonaTucson, Arizona
- CI TrialsBellflower, California